CereVasc, Inc. is dedicated to advancing medical technology through the development of the eShunt® System, which aims to provide a minimally invasive treatment for communicating hydrocephalus, a prevalent neurological condition affecting both children and adults. This innovative device seeks to address the limitations of current treatment methods, which often involve invasive neurosurgical procedures with lower success rates compared to other interventions. By improving patient outcomes and potentially reducing the costs associated with surgical treatments, the eShunt System represents a significant advancement in cerebrospinal fluid (CSF) management and therapy.

In addition to the eShunt System, CereVasc is expanding its portfolio with follow-on products designed to enhance the care of patients with various neurovascular diseases. These novel concepts aim to facilitate therapy delivery across the blood-brain barrier, thereby minimizing the risks and complications associated with traditional methods such as intrathecal injections or Ommaya reservoir placements. The company has also established a robust patent portfolio, securing exclusive rights to key technologies and improvements related to endovascular CSF shunt treatments, which underscores its commitment to innovation in the field of neurology.

United States

CereVasc, Inc. is a clinical-stage, medical device company developing novel treatments for neurological diseases. The company is focused on developing the eShunt™ System for the treatment of patients with hydrocephalus. CereVasc aims to improve patient outcomes and redefine the treatment of communicating hydrocephalus through its innovative medical devices.

CereVasc, Inc.

Company Details